MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.
The medtech industry has made a lot of mass media headlines in recent weeks as Medtronic’s (NYSE:MDT) $43 billion acquisition of Covidien (NYSE:COV) became a political football.
The merger helped keep Medtronic at the top of last month’s internet-search hierarchy, in addition to updates from the company’s diabetes division, a U.S. recall and new plans for China.
Aesthetics company Allergan (NYSE:AGN) jumped up to 2nd-place as its civil war raged on, with both the device maker and activist investor Valeant Pharmaceuticals vying for control of the company.
Johnson & Johnson (NYSE:JNJ) returns to the list with a spate of stories in the wake of the company’s earnings, including a major buyback, an eye for acquisitions and a high-profile recall of power morcellators associated with an increased cancer risk.
Boston Scientific (NYSE:BSX) dropped to the bottom of the list, but not for a lack of news. The company announced legal updates, regulatory wins and clinical trial results last month.
Medtronic
- White House rails against Medtronic-style corporate inversions
- Medtronic lands FDA approval to bring 3rd artificial cervical disc to the U.S.
- Medtech’s top stent-makers land SharedClarity contracts
- Medtronic pays up to $105 million for Visualase
- Medtronic, Lifetech expand China pacemaker deal
- Medtronic settles insulin pump beef for $2.8M
- Medtronic has big dreams for China’s diabetes market
- Report: Medtronic shareholder sues to block Covidien merger
- Medtronic tallies 175 apps for iPhones and iPads
- Medtronic fights tax dodging rhetoric in Covidien merger
- Could Medtronic-Covidien deal get caught in anti-inversion legislation?
- Medtronic CEO’s pay jumped 35% last year
- Shareholder files class action lawsuit to block Covidien-Medtronic merger
- GE Healthcare reorganizes after losing another to Medtronic
- Ex-Medtronic exec Mackin is CryoLife’s new CEO
- Medtronic lays off 40 in Minnesota
- Covidien taps integration chief to navigate Medtronic merger
- Podcast: Medical device execs react to Medtronic-Covidien deal, M&A activity at DeviceTalks Minnesota
- Diabetes: Medtronic insulin pump beats daily injections for managing Type II
- Medtronic issues Class I recall of Duet neuro drainage and monitoring systems
- Study: Early CoreValve patients saw growing leakage, mortality risk
- Podcast: Covidien’s Enxing Seng talks Medtronic merger, future of medicine at DeviceTalks
Allergan
- Allergan cuts 1,500 jobs, faces SEC complaint
- A countdown to failure for Valeant’s hostile $53B Allergan takeover
- Allergan renews fight against hostile Valeant takeover
- Valeant, hedge fund look to oust Allergan board members
Johnson & Johnson
- Johnson & Johnson recalls power morcellators over cancer risk
- Johnson & Johnson loses bids to dismiss Pinnacle bellwethers
- Johnson & Johnson launches $5B buyback
- Johnson & Johnson eyes acquisitions in cardiovascular, elsewhere
- Pharma delivers another beat & raise quarter for Johnson & Johnson
- FDA panel inconclusive on power morcellators
- Diabetes: UniStrip levels anti-trust charges against Johnson & Johnson’s LifeScan
- Guidant can’t slip breach-of-contract charges in Johnson & Johnson suit
- DePuy Synthes confirms layoffs
- J&J to cut 400 jobs from DePuy Synthes division
- Oregon settles DePuy ASR suit with Johnson & Johnson for $4M
- Johnson & Johnson closes Ortho-Clinical Diagnostics sale
Covidien
- Medtronic shareholder sues to block Covidien merger
- Medtech’s top stent-makers land SharedClarity contracts
- Haemonetics taps outgoing Covidien CFO Dockendorff for board
- Covidien’s Q3 sales meet The Street, earnings top estimates
- Report: Medtronic shareholder sues to block Covidien merger
- Covidien promotes Hanson to group president role
- Medtronic fights tax dodging rhetoric in Covidien merger
- Could Medtronic-Covidien deal get caught in anti-inversion legislation?
- Covidien to launch Emprint soft tissue ablation device
- Covidien launches new Trellis clot-busting device
- Covidien’s Nellcor and CAS Medical settle dispute for $275k
- Covidien logs $180M charge over pelvic mesh lawsuits
- Shareholder files class action lawsuit to block Covidien-Medtronic merger
- Covidien taps integration chief to navigate Medtronic merger
- Podcast: Medical device execs react to Medtronic-Covidien deal, M&A activity at DeviceTalks Minnesota
- Podcast: Covidien’s Enxing Seng talks Medtronic merger, future of medicine at DeviceTalks
Boston Scientific
- Vascular Solutions, Boston Scientific settle catheter patent spat
- Boston Scientific prevails in 1st pelvic mesh trial
- Boston Scientific, other medtech giants weigh in on mega-mergers
- Medtech’s top stent-makers land SharedClarity contracts
- Boston Scientific lands another E.U. win, this time for Agent balloon
- Boston Scientific beats The Street with Q2 sales, earnings
- Boston Scientific aims to simplify intravascular imaging with Polaris
- Boston Scientific loses bids to exclude testimony in pelvic mesh trials
- Boston Scientific’s bare-metal Rebel stent comes to the U.S.
- Boston Scientific lands Euro approval for mid-size Lotus valve
- Boston Scientific wins CE Mark for Ranger drug-eluting balloon
- Fitch affirms Boston Scientific’s bond rating
- Guidant can’t slip breach-of-contract charges in Johnson & Johnson suit
- Ex-Boston Scientific finance chief Capello lands at Ortho-Clinical Diagnostics
- Stealthy Mvalve raises $15M from Boston Scientific
- Boston Scientific’s Watchman misses 1 of 2 efficacy goals in PREVAIL trial